Melanoma Biobank

核心A-黑色素瘤生物库 人类癌细胞的繁殖一直是癌症生物学的重要组成部分，包括精液 在黑色素瘤中发现BRAF突变。从历史上看，癌症株已被证明是一种强大的 用于筛选新的治疗化合物和分离敏感性分子决定因素的系统 到抗癌药物。核心A-黑色素瘤生物库(MBB)的主要任务是建立一个关键的 接受选择性BRAF抑制剂或其他药物治疗的患者的一组黑色素瘤细胞系 新奇的特工。来自A岩芯的重要衍生品，以及带注释的标本，将向其他人提供 用于可能出现的目标候选的分子验证和功能验证的P01 从不同的屏幕。核心A的具体目标是(1)提供黑色素瘤的中心来源 在开始使用选择性BRAF抑制剂(SBI)之前和在经历 治疗，(2)提供细胞上的突变、拷贝数、表达和途径激活谱 LINE和(3)提供选择性BRAF抑制剂和其他靶向治疗的敏感性数据 比较不同靶向药物的药物反应和(4)维护临床数据库和 来自靶向治疗试验患者的组织信息库。这最后一个目标将利用现有的 提供资金，并将在整个翻译工作中提供相关谜题的关键一块。由 在供资期间结束时，POI内所有项目和核心的成功整合将产生 史无前例的一套组织标本和生命细胞，装饰着细致的临床注释和深入的 分子图谱。

Core A - Melanoma Biobank The propagation of human cancer cells has been a vital part of cancer biology including the seminal discovery of BRAF mutations in melanoma. Historically, cancer lines have proven to be a powerful system for screening novel therapeutic compounds and for isolating molecular determinants of sensitivity to anti-cancer drugs. The main charge of Core A- the Melanoma Biobank (MBB)- is to establish a critical set of melanoma cell lines from patients who undergo treatment with selective Braf inhibitors or other novel agents. Vital derivatives from Core A, along with annotated specimens, will be available to the rest of the P01 for molecular verification and functional validation of target candidates which may emerge from the various screens. The Specific Aims of Core A are (1) to provide a central source of melanoma cells obtained prior to initiation of selective Braf inhibitors (SBIs) and during relapse while undergoing treatment, (2) to provide mutational, copy number, expression and pathway actiyation profiles on cell lines and (3) to provide sensitivity data for selective BRAF inhibitors and other targeted therapies and to compare drug responses across various targeted agents and (4) to maintain a clinical database and tissue repository derived from patients on targeted therapy trials. This last Aim will leverage extant funding and will provide a critical piece of the correlative puzzle in the overall translational effort. By the end of the funded period, successful integration of all Projects and Cores within the POI will yield an unprecedented set of tissue specimens and vital cells adorned with meticulous clinical annotation and in-depth molecular profiling.